检索结果-南通市图书馆

Impact of antagonist peptides and chelators on the diagnostic performance of PET/CT using gallium-68 labeled somatostatin receptor antagonists

引用

Journal of Pancreatology 2022年第3期5卷 15-39页

作者： Haiqun Xing Wenjia Zhu Yuejuan Cheng Qiao Yang Ru Jia Hong Zhao Chunmei Bai Li Huo Wenming Wu Nuclear Medicine Department State Key Laboratory of Complex Severe and Rare DiseasesCenter for Rare Diseases ResearchBeijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear MedicinePeking Union Medical College HospitalChinese Academy of Medical Science and Peking Union Medical CollegeBeijingChina Department of Oncology Peking Union Medical College HospitalBeijingChina Department of gastrointestinal Oncology the fifth Medical CenterGeneral Hospital of PLABeijingChina Department of Hepatobiliary Surgery National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijingChina Department of General Surgery Peking Union Medical College HospitalPeking Union Medical CollegeChinese Academy of Medical SciencesBeijingChina

Objective:Different SSTR2 antagonists have been developed.This study aims to evaluate the impact of different peptides and chelators on the diagnostic performance of SSTR2 antagonists in well-differentiated NETs.Methods:In this prospective study,participants were equally randomized into two arms:Arm A,participants would undergo a whole-body 68ga-nodaga-LM3 PET/CT scan on the 1st day and 68ga-DOTA-LM3 PET/CT scan on the 2nd day;Arm B,participants would undergo a whole-body 68ga-nodaga-LM3 PET/CT scan on the 1st day and 68ga-nodaga-jr11 PET/CT scan on the 2nd day.Biodistribution in normal organs,lesion detection ability,and tumor uptakes were compared within each Arm.Results:A total of 40 participants(age,49.5±13.4,21 men),20 in each arm,were recruited in the study.In Arm A,68ga-DOTA-LM3 showed lower background.However,the lesion detection ability(overall lesion detected,445 versus 548,P=0.005)and the lesion uptake(overall lesions SUVmax,19.8±17.2 versus 35.3±28.8,P68ga-nodaga-LM3.In Arm B,both 68ga-nodaga-LM3 and 68ga-nodaga-jr11 showed similar biodistribution and lesion uptake(SUVmax,28.5±23.8 versus 25.0±20.0,P68ga-nodaga-LM3 and 68ga-nodaga-jr11 outperformed 68ga-DOTA-LM3 with higher lesion uptake and detection ability,of which 68ga-nodaga-LM3 had marginally but significantly higher lesion uptake.

关键词： Somatostatin receptor antagonist 68ga-nodaga-LM3 68ga-DOTA-LM3 68ga-nodaga-jr11 neuroendocrine tumor

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：